Personalized Medicine in Severe Asthma: Bridging the Gaps.
作者信息
García-Rivero Juan Luis, García-Moguel Ismael
机构信息
Respiratory Department, Marqués de Valdecilla University Hospital, Valdecilla Research Institute (IDIVAL), Santander, Spain.
Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
出版信息
Open Respir Arch. 2024 Sep 24;6(4):100368. doi: 10.1016/j.opresp.2024.100368. eCollection 2024 Oct-Dec.
Abstract
摘要
相似文献
1
Personalized Medicine in Severe Asthma: Bridging the Gaps.重度哮喘的个性化医疗：弥合差距
Open Respir Arch. 2024 Sep 24;6(4):100368. doi: 10.1016/j.opresp.2024.100368. eCollection 2024 Oct-Dec.
2
Applying personalized medicine to adult severe asthma.将个体化医学应用于成人严重哮喘。
Allergy Asthma Proc. 2021 Jan 1;42(1):e8-e16. doi: 10.2500/aap.2021.42.200100.
3
Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.严重哮喘的个体化医学：从生物标志物到生物制剂。
Int J Mol Sci. 2023 Dec 22;25(1):182. doi: 10.3390/ijms25010182.
4
Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma and Concomitant Severe Chronic Urticaria: An Example of Personalized Medicine?美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘合并重度慢性荨麻疹患者的疗效：个性化医疗的一个实例？
J Investig Allergol Clin Immunol. 2023 Feb 17;33(1):54-56. doi: 10.18176/jiaci.0770. Epub 2021 Nov 29.
5
Contemporary Concise Review 2020: Asthma.当代简明综述 2020：哮喘。
Respirology. 2021 Aug;26(8):804-811. doi: 10.1111/resp.14099. Epub 2021 Jun 23.
6
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.生物制品个体化医学治疗严重 2 型哮喘：现状与展望。
MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14.
7
Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.弥合个性化医疗价值评估中的差距：对跨利益相关者和科学学科的结果指标需求的综述
Public Health Genomics. 2019;22(1-2):16-24. doi: 10.1159/000501974. Epub 2019 Aug 27.
8
Asthma: personalized and precision medicine.哮喘：个性化与精准医学。
Curr Opin Allergy Clin Immunol. 2018 Feb;18(1):51-58. doi: 10.1097/ACI.0000000000000416.
9
How to apply the personalized medicine in obesity-associated asthma?如何将个体化医学应用于肥胖相关性哮喘？
Expert Rev Respir Med. 2020 Sep;14(9):905-915. doi: 10.1080/17476348.2020.1780123. Epub 2020 Jul 7.
10
Chronic inflammation: Cross linking insights from Ayurvedic Sciences, a silver lining to systems biology and personalized medicine.慢性炎症：结合阿育吠陀科学的见解，为系统生物学和个性化医学带来一线希望。
J Ayurveda Integr Med. 2024 Jul-Aug;15(4):101016. doi: 10.1016/j.jaim.2024.101016. Epub 2024 Jul 16.
本文引用的文献
1
Tezepelumab in patients with allergic and eosinophilic asthma.特泽布尔单抗治疗过敏性和嗜酸性哮喘患者。
Allergy. 2024 May;79(5):1134-1145. doi: 10.1111/all.15986. Epub 2023 Dec 26.
2
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.生物制剂治疗过敏性重症哮喘患者的疗效，总体及基于血嗜酸性粒细胞计数：文献综述。
Adv Ther. 2023 Nov;40(11):4721-4740. doi: 10.1007/s12325-023-02647-2. Epub 2023 Sep 12.
3
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.度普利尤单抗治疗未控制或依赖口服皮质类固醇的过敏性和非过敏性哮喘患者的疗效。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):873-884.e11. doi: 10.1016/j.jaip.2022.11.044. Epub 2022 Dec 23.
4
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.tezepelumab治疗有严重过敏性哮喘证据患者的疗效：3期NAVIGATOR研究结果
Clin Exp Allergy. 2023 Apr;53(4):417-428. doi: 10.1111/cea.14256. Epub 2022 Dec 12.
5
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.重度哮喘的真实世界生物制剂使用及转换模式：来自国际重度哮喘注册研究和美国CHRONICLE研究的数据
J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022.
6
Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.嗜酸粒细胞性和非嗜酸粒细胞性哮喘：全球真实严重哮喘队列中表型特征的专家共识框架。
Chest. 2021 Sep;160(3):814-830. doi: 10.1016/j.chest.2021.04.013. Epub 2021 Apr 19.
7
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma.中重度哮喘中过敏性、嗜酸性粒细胞和 2 型炎症亚型的重叠。
Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7.
8
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担：2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
9
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.度普利尤单抗治疗哮喘和常年性变应性鼻炎患者的临床结局疗效。
Ann Allergy Asthma Immunol. 2020 Nov;125(5):565-576.e1. doi: 10.1016/j.anai.2020.05.026. Epub 2020 May 28.
10
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.美泊利珠单抗替代奥马珠单抗治疗未控制的严重嗜酸性粒细胞性哮喘的临床获益。
Allergy. 2019 Sep;74(9):1716-1726. doi: 10.1111/all.13850. Epub 2019 Jul 1.
Zotero 插件